Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Broadcom Inc (AVGO) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance

Broadcom IncTrade
Charles River Laboratories Intl. IncTrade

Price performance (Past 24H)

Key statistics

Broadcom Inc vs Charles River Laboratories Intl. Inc — how do they compare? Broadcom Inc trades at $390.11 (market cap $1.85T), while Charles River Laboratories Intl. Inc trades at $226.11 (market cap $11.14B). The key difference: Broadcom Inc is far larger — about 166.1× Charles River Laboratories Intl. Inc's market cap, and Broadcom Inc pays a 0.67% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.

AVGOCRL
Market Cap
$1.85T$11.14B
Sector
TechnologyHealth
52-Week High
$481.57$233.60
52-Week Low
$278.59$145.57
Enterprise Value
$1.90T$14.00B
Dividend Yield
0.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Broadcom Inc

Broadcom (AVGO) trades at $384.05, down 3.98% on the day, but maintains strong fundamental momentum with consistent earnings beats and robust revenue growth. The stock shows bullish technical signals with support at $380 and resistance at $392, while fundamentals reveal impressive profitability with 38.85% net margins and 37.28% ROE. Recent analyst coverage remains overwhelmingly positive with 86% buy ratings.

AVGO presents a compelling growth story with AI-driven revenue expansion and strong cash flow generation, though elevated valuation multiples (P/E 63.9) and high debt levels warrant caution. The consensus price target of $509.70 suggests significant upside potential if execution continues, but investors should monitor competitive pressures in the semiconductor space.

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Broadcom Inc

Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.

Read more on AVGO

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL